A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.
← catalyst calendarNCT07161687 · readout in 1,330 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
50estimated
Sites
1
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-30 | actual | When the study began enrolling |
| Primary completion | 2030-04-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-04-11 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hemophilia A or B
Intervention
- Drug: Marstacimab — also filed as Hympavzi
Primary outcome
what the primary-completion date above is the date OFNumber of the participants with adverse drug reactions
measured The evaluation period is from the first dose of Himpavzi up to 156 weeks (3 years).
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed